Interventional Oncology Market Report: Unlocking Growth Potential and Addressing Challenges

United States of America – July 23, 2025 – The Insight Partners is proud to announce its latest market research publication, "Interventional Oncology Market: An In-depth Analysis of the Global Landscape." This report offers a comprehensive overview of the interventional oncology market, examining the current dynamics, recent developments, and projected growth trajectory from 2025 to 2031.

Overview of the Interventional Oncology Market

The interventional oncology market is witnessing transformative growth, driven by advances in minimally invasive procedures, rising global cancer incidence, and the increasing adoption of image-guided therapies. Once limited to niche treatments, interventional oncology is now emerging as a vital component of multidisciplinary cancer care, reshaping how oncologists approach hard-to-treat tumors.

Key Findings and Insights

Market Size and Growth

• Historical Data (2021–2023): The interventional oncology market showed steady gains as hospitals and specialty clinics integrated image-guided techniques into oncology workflows.

• Forecast (2025–2031): The global market is projected to reach significant valuation by 2031, expanding at a CAGR of 8.2%.

• Key Factors:

  • Increasing preference for minimally invasive therapies.

  • Technological advancements in imaging and device precision.

  • Growing elderly population and cancer prevalence.

  • Expanding applications of interventional oncology in multiple cancer types.

Market Segmentation

By Product

• Embolization Devices – Including drug-eluting beads and microspheres used to block tumor blood supply.

• Ablation Devices – Such as radiofrequency and microwave ablation systems designed to thermally destroy cancer cells.

• Support Devices – Including catheters, guidewires, and delivery systems enabling accurate device placement.

By Procedure

• Thermal Tumor Ablation – Utilizes high temperatures to destroy cancer cells (e.g., RFA, MWA).

• Non-Thermal Tumor Ablation – Employs cryoablation and irreversible electroporation (IRE) for temperature-sensitive scenarios.

• Transcatheter Arterial Chemoembolization (TACE) – Delivers chemotherapy directly to the tumor with embolic agents.

• Transcatheter Arterial Radioembolization (SIRT) – Targets liver tumors using radioactive microspheres.

• Transcatheter Arterial Embolization (TAE) – Also known as bland embolization, cuts off tumor blood supply without drugs.

By Cancer Type

• Liver Cancer – A major application area for embolization and ablation therapies.

• Lung Cancer – Increasing use of thermal ablation in early-stage, inoperable cases.

• Bone Cancer – Palliative treatments and pain management through ablation.

• Kidney Cancer – Image-guided ablation as an alternative to surgical resection.

• Other Cancers – Including pancreatic, breast, and soft tissue tumors.

Spotting Emerging Trends

Technological Advancements

• Next-gen ablation systems with robotic precision.

• AI-enhanced image navigation and intra-procedural monitoring.

• Miniaturized catheter systems for targeted, less traumatic treatments.

Changing Consumer Preferences

• Shift toward outpatient, non-surgical cancer treatment options.

• Increasing demand for pain-reducing, organ-sparing therapies.

• Rising awareness of alternative cancer therapies in emerging economies.

Regulatory Changes

• Accelerated FDA pathways and CE approvals for novel devices.

• Reimbursement expansions supporting interventional oncology in public and private healthcare systems.

• Guidelines integrating interventional therapies into standard cancer care protocols.

Growth Opportunities

• Expanding Access in Developing Regions – Increasing availability of skilled radiologists and equipment in Asia, Latin America, and Africa.

• Integration with AI and Imaging – Smart systems enabling real-time procedural guidance and outcome prediction.

• New Clinical Indications – Broader use in metastatic cancers and palliative care.

• Strategic Collaborations – Partnerships between device manufacturers and cancer research institutions to foster innovation.